Skip to content
★ Sign in to follow
CS

Cross Shore Discovery Fund Stock: price and insider trades · United States

No insider purchase over the last 90 days. The latest, by Kuttner Neil, was filed 02 May 2023.

Cross Shore Discovery Fund: what insiders have been doing

Cross Shore Discovery Fund, classified in the Finance & Banking sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). No insider at Cross Shore Discovery Fund has published a filing in the past twelve months. The most recent one dates from 12 February 2025.

Over the whole record (from 2015), the tally stands at 20 purchases and 7 sales.

Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Insider Decl.
35
Thresholds
n/a
Buy Volume
€14,526
20 ops. · all time
Sell Volume
€418,700
7 ops. · all time

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

· cache

US$75.06
Last declaration on 12 February 2025
Declarations35 total
  • ●
    Related company / holdingExecutives
    14M USD10SEC
    156,181.16 shares@ US$87.36100.0% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-25-000969:0
  • ●
    Related company / holdingExecutives
    2M USD10SEC
    18,557.68 shares@ US$87.36100.0% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-25-000970:0
  • ●
    Executives
    298,802 USD3SEC
    3,420.35 shares@ US$87.368.0% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-25-000836:1
  • ●
    Executives
    2M USD5SEC
    18,498.46 shares@ US$87.3629.7% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-25-000837:1
  • ●
    Executives
    1M USD4SEC
    14,732.19 shares@ US$87.3622.4% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-25-000838:1
  • ●
    Executives
    3M USD10SEC
    39,375.47 shares@ US$87.36100.0% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-25-000836:0
  • ●
    Executives
    4M USD10SEC
    51,113.5 shares@ US$87.36100.0% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-25-000838:0
  • ●
    Executives
    3M USD10SEC
    38,739.26 shares@ US$87.36100.0% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-25-000837:0
  • ▼
    Executives
    0SEC
    3,962.48 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-24-000008:0
  • ▲
    Executives
    0SEC
    500,000 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-23-002762:0
    Canonical exit: 30 Jul 2023 (T+90)
  • ▼
    Executives
    0SEC
    500,000 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-22-000562:0
  • ▲
    Executives
    0SEC
    1,000,000 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-22-000561:0
    Canonical exit: 1 Apr 2022 (T+90)
  • ▲
    Executives
    0SEC
    2,769.32 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-21-005653:0
    Canonical exit: 30 Nov 2021 (T+90)
  • ▲
    Executives
    1,029 USD4SEC
    10.77 shares@ US$95.510.0% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-21-002927:0
    Canonical exit: 30 May 2021 (T+90)
  • ▼
    Executives
    0SEC
    2,000,000 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-21-000017:0
  • ▼
    Executives
    0SEC
    250,000 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-20-006186:0
  • ▼
    President, Principal ExecutiveExecutives
    0SEC
    250,000 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-20-006183:0
  • ▼
    Executives
    0SEC
    150,000 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-20-006187:0
  • ▲
    Executives
    0SEC
    519.81 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-20-006187:1
    Canonical exit: 30 Dec 2020 (T+90)
  • ▲
    Executives
    0SEC
    250,000 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-20-004401:0
    Canonical exit: 29 Sept 2020 (T+90)
  • ▲
    Executives
    0SEC
    250,000 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-20-004398:0
    Canonical exit: 29 Sept 2020 (T+90)
  • ▲
    President, Principal ExecutiveExecutives
    0SEC
    250,000 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-20-004413:0
    Canonical exit: 29 Sept 2020 (T+90)
  • ▲
    Executives
    0SEC
    4,725.12 sharesShares of beneficial interest, par value $.001 per shareSEC:0000919574-20-004132:0
    Canonical exit: 30 Aug 2020 (T+90)
  • ▲
    Executives
    3,062 USD2SEC
    34.97 shares@ US$87.560.1% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-20-003694:0
    Canonical exit: 30 Jun 2020 (T+90)
  • ▲
    Executives
    12,054 USD2SEC
    111.85 shares@ US$107.770.3% of flowShares of beneficial interest, par value $.001 per shareSEC:0000919574-19-005998:0
    Canonical exit: 30 Oct 2019 (T+90)

25 of 35 declarations

About Cross Shore Discovery Fund

Cross Shore Discovery Fund is a U.S.-based investment vehicle registered with the SEC and historically connected to the U.S. listed-fund universe. It is structured as a Delaware statutory trust and was based in Cincinnati, Ohio, at 225 Pictoria Drive, Suite 450, while the investment adviser, Cross Shore Capital Management, LLC, operated from Great Neck, New York. The fund was created in 2012, and public registry data now shows it as inactive following a liquidation effective December 31, 2024. For investors reviewing SEC Form 4-related insider activity, that status change is a crucial context point. ([lei.bloomberg.com](https://lei.bloomberg.com/leis/view/549300FIOYAHZ5RDKV81))

In business terms, Cross Shore Discovery Fund is not an operating company with products, factories, or consumer brands. Its value proposition is investment management: the fund’s adviser aimed to deliver superior risk-adjusted returns across a full market cycle, with lower drawdowns and volatility than broad U.S. equity indices. The fund’s historical portfolio construction leaned toward growth-oriented strategies, with significant exposure to information technology and biotechnology. That made the vehicle more of a specialized growth allocation tool than a broad market fund. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001609706/000158064223003164/cross-shore_ncsr.htm))

Read moreShow less

From a competitive standpoint, the fund competed in the niche segment of alternative and specialized investment products, where performance depends on asset allocation discipline, manager selection, and sector positioning. Its annual report notes that technology exposure had previously been a source of underperformance, prompting a reduction in that weighting, while biotechnology remained an important sleeve in the portfolio. That suggests a manager willing to rebalance exposure tactically rather than remain rigidly committed to a single theme. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001609706/000158064223003164/cross-shore_ncsr.htm))

Geographically, the fund was firmly anchored in the United States, with the principal executive office in Cincinnati, Ohio, and the adviser in New York. For French, Belgian, and Swiss investors, the relevant lens is therefore U.S. regulatory oversight, SEC reporting, and the fund’s status as a U.S. investment company. The recent tender-offer filing and the registered liquidation event indicate that the fund’s lifecycle has moved into wind-down mode, which is materially more important than any standard operating KPI. ([streetinsider.com](https://www.streetinsider.com/SEC%2BFilings/Form%2BSC%2BTO-I%2BCROSS%2BSHORE%2BDISCOVERY%2BFiled%2Bby%3A%2BCROSS%2BSHORE%2BDISCOVERY%2BFUND/23551667.html))

In practical terms, Cross Shore Discovery Fund should be understood as a small, specialized U.S. fund vehicle that historically targeted growth, technology, and biotechnology opportunities, but whose recent regulatory record shows liquidation rather than expansion. For equity analysts and investors, the most relevant takeaways are the U.S. domicile, the SEC-regulated structure, the growth-biased investment mandate, and the fact that the fund no longer appears to be an ongoing active operating platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001609706/000158064223003164/cross-shore_ncsr.htm))